Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06536374 · ClinicalTrials.gov registry record · Phase 2

Folate Study in Men With Advanced Prostate Cancer

A Phase 2 study, sponsored by University of California, San Diego.

Not yet
Registry status
Phase 2
Development phase
50
Enrollment target

NCT06536374 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Diego. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06536374, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Diego.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target

Study Summary

The researchers hope to learn if Trimethoprim, 150mg taken daily for 3 months, is a safe and effective way to reduce folate levels at time of Androgen Deprivation Therapy (ADT) in men with advanced prostate cancer. This study will help find out what effects, good and/or bad, this drug has on people who take it and on its effect on the disease. The safety of this drug in humans has been tested in prior research studies; however, some side effects may not yet be known.

Interventions

  • DRUG Trimethoprim Tablets

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2026-06
Est. Completion 2027-12
Phase Phase 2

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT06536374

The ClinicalTrials.gov registry entry for NCT06536374 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Trimethoprim Tablets is the first listed.

NCT06536374 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06536374 about?

NCT06536374 is a clinical study titled "Folate Study in Men With Advanced Prostate Cancer". The researchers hope to learn if Trimethoprim, 150mg taken daily for 3 months, is a safe and effective way to reduce folate levels at time of Androgen Deprivation Therapy (ADT) in men with advanced prostate cancer. This study will help find out what effects, good and/or bad, this drug has on people...

What is the current status of trial NCT06536374?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-06. Estimated completion is 2027-12.

What interventions are being tested in trial NCT06536374?

The interventions under investigation include: Trimethoprim Tablets (DRUG).

Who is sponsoring clinical trial NCT06536374?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.